For research use only. Not for therapeutic Use.
N-Carbamoyl Linagliptin is a derivative of linagliptin, a medication used to treat type 2 diabetes. This modification involves the addition of a carbamoyl group to the linagliptin molecule, potentially altering its pharmacokinetic properties or target specificity. Such modifications are common in drug development to enhance efficacy, reduce side effects, or improve bioavailability, contributing to the optimization of therapeutic agents for clinical use.
| Catalog Number | R033702 |
| CAS Number | NA |
| Synonyms | 1-((1R)-3-(7-(But-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)cyclohexyl)urea; |
| Molecular Formula | C₂₇H₃₀N₈O₃ |
| Purity | ≥95% |
| Storage | -20°C |
